Johnson & Johnson Nordic AB, a Johnson & Johnson company, announced the acquisition of Amic, a privately held Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings. The acquisition will provide J&J’s Ortho-Clinical Diagnostics with access to a high performance technology platform. As a result of the acquisition, Johnson & Johnson expects to incur an estimated one-time after-tax charge of approximately $40 million during the second quarter of 2008 related to the expensing of in-process research and development. Other terms of the transaction were not disclosed.